Interim Report – January to March 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter 2018.

Financial Highlights

• Revenue for the 1st Quarter 2018 amounted to SEK 22.5 (31.1) m.
• Operating result for the quarter amounted to SEK -37.0 (2.3) m.
• Net result for the quarter amounted to SEK -37.0 (2.3) m.
• Cash flow for the quarter amounted to SEK 8.6 (18.0) m.
• Cash and cash equivalents at the end of the period amounted to SEK 249.9 (145.1) m.

Significant Events during the Reporting Period

• A 100 patient multicenter Phase II study of ABY-035 in Germany, commenced in March 2018.
• A Phase I proof-of-principle study of ABY-039 in the UK, commenced in March 2018.
• The rights issue of shares resolved at the EGM on November 23, completed in January, was fully subscribed for with corresponding proceeds of SEK 199m.

Significant Events after the close of the Reporting Period

• A Clinical Trial Application (CTA) for a multicenter investigator led clinical phase II/III study with [68Ga]ABY-025 in Sweden, Denmark and Finland, was submitted in April, 2018 to the Medical Product Agency (MPA).
• The Annual General Meeting (AGM) in 2018 is scheduled for June 13 at 1 PM at the company’s premises at Gunnar Asplunds Allé 24 in Solna.